Prelude Capital Management’s GSK GSK Stock Holding History

Prelude Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-700	Closed	-$1.01M	–	1301
2022 Q4	$1.01M	Buy	+700	New	+$23.3K	0.05%	378
2022 Q1	–	Sell	-60,560	Closed	-$3.34M	–	1985
2021 Q4	$3.34M	Hold	60,560	–	–	0.09%	173
2021 Q3	$2.89M	Buy	+60,560	New	+$3.04M	0.07%	203
2021 Q2	–	Sell	-12,560	Closed	-$560K	–	1763
2021 Q1	$560K	Buy	12,560 +480	+4%	+$21.8K	0.01%	844
2020 Q4	$556K	Sell	12,080 -80	-0.7%	-$3.67K	0.01%	690
2020 Q3	$572K	Buy	+12,160	New	+$609K	0.03%	407

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's GSK Position: Q1 2023 in Review

Prelude Capital Management sold out of GSK (GSK) in Q1 2023, closing a stake of 30,391 shares — an estimated $1.07M sold.

Prelude Capital Management first reported a position in GSK in Q1 2017 and held it in 4 quarters. The position peaked at $1.8M in Q1 2017. 809 funds tracked by Wall St. Rank hold GSK as of Q1 2023.

Prelude Capital Management reported no remaining GSK position as of Q1 2023 after selling out during the quarter.
Prelude Capital Management sold 30,391 GSK shares in Q1 2023, an estimated $1.07M.
Prelude Capital Management first reported a position in GSK in Q1 2017 and held it in 4 quarters.
Prelude Capital Management's GSK position peaked at $1.8M in Q1 2017.
809 funds tracked by Wall St. Rank held GSK as of Q1 2023.

Based on Prelude Capital Management's 13F filing for Q1 2023, filed 15 May 2023.